Dataset from Randomised, Double-Blind, Placebo-Controlled, 5-Way Cross-Over Study to Assess the Efficacy (Bronchoprotection) and Safety of a Single Dose of Orally Inhaled BI 1744 CL (2, 5, 10 and 20ug) in Patients With Intermittent Asthma
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00006620
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this study is to assess the efficacy (bronchoprotection) and safety
of single doses of BI 1744 CL inhalation solution (2, 5, 10 and 20 mcg) delivered via the
Respimat® inhaler, in patients with intermittent asthma.
创建时间：
2024-11-26
